Herceptin Hylecta FDA Approval History
FDA Approved: Yes (First approved February 28, 2019)
Brand name: Herceptin Hylecta
Generic name: trastuzumab and hyaluronidase-oysk
Dosage form: for Subcutaneous Injection
Company: Genentech, Inc.
Treatment for: Breast Cancer
Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) is a combination of the approved HER2/neu receptor antagonist trastuzumab (Herceptin) and recombinant human hyaluronidase PH20 (an enzyme that helps to deliver trastuzumab under the skin) indicated for the treatment of HER2-overexpressing breast cancer.
Development timeline for Herceptin Hylecta
| Date | Article |
|---|---|
| Feb 28, 2019 | Approval FDA Approves Herceptin Hylecta for Subcutaneous Injection in Certain HER2-Positive Breast Cancers |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
